Clinical trials: Bone Diseases, Endocrine
Acromegaly
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
- Trial name
- SALSA (NCT00447499)
- Testing
- Somatuline Autogel (lanreotide acetate), Home administration
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ipsen
Acromegaly
Korean Regulatory Post Marketing Surveillance for Somavert
Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
- Trial name
- NCT05131100
- Testing
- Somavert
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Pfizer
Growth Hormone Deficiency
Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON
The purpose of this study is to investigate long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner syndrome.
- Trial name
- NCT01365351
- Testing
- Growth hormone
- Where
- 59 sites in Germany
- Volunteers
- 1,034 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Deficiency (GHD)
Treatment of Children With Insufficient Secretion of Growth Hormone
The purpose of this study is to compare a new weekly administered growth hormone preparation with standard daily treatment in children with insufficient secretion of growth hormone
- Trial name
- BPLG-004 (NCT00271518)
- Testing
- growth hormone (somatropin)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- LG Life Sciences
Growth Hormone Deficiency (GHD)
Development of a Personalized Growth Hormone Treatment Profile (PGTP) Report for Pediatric Endocrinology
The goal of this observational study is to learn how to make growth hormone treatment more personalized for children. The main questions it aims to answer are: How can information about treatment adherence and patient experiences…
- Trial name
- PGTP (NCT06830525)
- Testing
- ACDP® and growth hormone treatment
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luis Fernandez Luque
Growth Hormone Deficiency
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad of population of children.
- Trial name
- NCT02380235
- Testing
- PEG-somatropin
- Where
- 12 sites in China
- Volunteers
- 600 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
- Trial name
- SkyPASS (NCT05775523)
- Testing
- No intervention
- Where
- 27 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Diabetes
Effect of the Superhydrophilic Surface of Lance CLEAR Implants on the Marginal Bone Loss and Survival in Diabetic and Non Diabetic Patients
The aim of this clinical, prospective study involving implants with a superhydrophilic surface is to compare the changes of the peri-implant tissues and the survival rate between diabetics and non-diabetics patients, after 12…
- Trial name
- NCT05979246
- Testing
- Lance CLEAR dental implant
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MIS Implant Technologies, Ltd
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.
- Trial name
- DOPAACRO 002 (NCT03045302)
- Testing
- BIM23B065
- Where
- 6 sites in Belgium, Hungary and 2 more
- Volunteers
- 4 people
- Sponsor
- Ipsen
Growth Hormone Deficiency
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)
As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life.
- Trial name
- NCT01605331
- Testing
- sustained-release recombinant human GH (SR-rhGH)
- Volunteers
- 132 people
- Sponsor
- LG Life Sciences
Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
- Trial name
- HCH (NCT06410976)
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 150 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Safety and Efficacy of Long-term Somatropin Treatment in Adults
This study is conducted in Europe. The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).
- Trial name
- NordiWIN (NCT01543880)
- Testing
- somatropin
- Where
- Germany
- Volunteers
- 752 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency
The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass.
- Trial name
- IGHD (NCT00630487)
- Testing
- Somatropin
- Where
- 2 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Pfizer
Short Stature Born Small for Gestational Age (SGA)
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
To assess the long-term safety of Genotropin(somatropin) on Small for Gestational Age (SGA) without epiphyseal closing.
- Trial name
- NCT01859949
- Testing
- Genotropin (somatropin)
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Pfizer
Acromegaly
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.
- Trial name
- NCT00616551
- Testing
- C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 65 people
- Sponsor
- Ambrilia Biopharma, Inc.
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Pituitary Disorders, Adult Growth Hormone Deficiency
Treatment of Adults With Growth Hormone Deficiency
The purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.
- Trial name
- NCT00294619
- Testing
- growth hormone
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- LG Life Sciences
Achondroplasia
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of…
- Trial name
- PROPEL3 (NCT06164951)
- Testing
- Infigratinib 0.25 mg/kg/day
- Where
- 27 sites in United States, Argentina and 8 more
- Volunteers
- 114 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research